This narrative review explores how gut microbial metabolites influence colorectal cancer. The authors examined the role these substances play in the body without testing them in a clinical trial. The study did not report specific patient numbers or a defined sample size.
The review found that certain metabolites can strengthen the gut barrier and reduce inflammation. These actions help block abnormal cell growth and trigger apoptosis, which stops cells from dividing uncontrollably. This process supports tumor suppression and may offer a protective effect against cancer development.
Conversely, other metabolites can release inflammatory cytokines and damage DNA. These actions drive uncontrolled proliferation and promote cancer growth. The review highlights that individual variation in host-microbe interactions and metabolite instability are important factors. Because specific biomarkers for patient selection are absent, applying these findings to individual patients requires caution.
The main takeaway is that targeting the gut microbiota-metabolite axis offers a promising path to more precise and effective treatments. However, this is a narrative review, not a clinical trial. The evidence is limited and does not prove cause and effect. Readers should understand that this information is early and not yet ready to change medical practice.
